Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Sectoral/ Thematic median (252 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 07 Mar 2024 – 20 Aug 2026, limited by Edelweiss Technology Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Edelweiss Technology Fund | Nifty 500 |
|---|---|---|
| 07 Mar 2024 | ₹100.00 | ₹100.00 |
| 21 May 2024 | ₹99.62 | ₹103.68 |
| 03 Aug 2024 | ₹112.38 | ₹113.82 |
| 17 Oct 2024 | ₹120.47 | ₹114.40 |
| 31 Dec 2024 | ₹121.92 | ₹109.50 |
| 15 Mar 2025 | ₹100.93 | ₹98.73 |
| 29 May 2025 | ₹111.79 | ₹111.87 |
| 12 Aug 2025 | ₹115.46 | ₹110.44 |
| 25 Oct 2025 | ₹120.85 | ₹115.91 |
| 08 Jan 2026 | ₹121.02 | ₹115.88 |
| 24 Mar 2026 | ₹105.24 | ₹103.09 |
| 06 Jun 2026 | ₹116.91 | ₹109.94 |
| 20 Aug 2026 | ₹127.24 | ₹115.06 |
| Metric | Edelweiss · Regular NAV ₹12.77 Very High risk ★★★★☆ 1Y | Category median Sectoral/ Thematic · 252 funds |
|---|---|---|
| +9.31% | +5.83% | |
| — | +15.63% | |
| — | +13.23% | |
| — | +13.85% | |
| +10.32% | +12.26% | |
| +9.79% | — | |
| — | +15.60% | |
| — | +14.52% | |
| — | +13.74% | |
| Risk | ||
| 15.01% | 15.62% | |
| 0.19 | 0.43 | |
| 0.26 | 0.59 | |
| -26.63% | -23.65% | |
| Nifty 500 | — | |
| — | +3.42% | |
| — | 0.95 | |
| — | 105.9% | |
| — | 93.6% | |
| 2.36% | 2.39% | |
| ₹700.63Cr | ₹1,161Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹100 | — | |
| ₹100 | — | |
| 4% | 45% | |
| Amit Vora | — | |
| 07 Mar 2024 | — | |
| 29 | — | |
| 47.7% | — | |
| -0.1% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.